We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 18, 2022

Lenvatinib Plus Letrozole in Postmenopausal Women With Hormone Receptor–Positive Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer
Clin. Cancer Res 2022 Apr 01;[EPub Ahead of Print], JSJ Lim, ALA Wong, SGW Ow, NYL Ngoi, GHJ Chan, YLE Ang, WQ Chong, SE Lim, YW Lim, M Lee, JRE Choo, HL Tan, WP Yong, RA Soo, DSP Tan, CE Chee, R Sundar, K Yadav, S Jain, L Wang, BC Tai, BC Goh, SC Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading